TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $160
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Yaron Werber maintains a Buy rating on Ascendis Pharma (NASDAQ:ASND) and raises the price target from $157 to $160.
October 21, 2024 | 5:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen analyst Yaron Werber has reaffirmed a Buy rating for Ascendis Pharma and increased the price target from $157 to $160, indicating a positive outlook.
The reaffirmation of a Buy rating and a slight increase in the price target by a reputable analyst suggests confidence in Ascendis Pharma's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100